Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA)
 for the treatment of patients with granulomatosis with polyangiitis (Wegener's
 granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the
 long-term safety and efficacy of this drug is not yet clear. This study proposes to follow
 patients who were enrolled in the RAVE study to determine if treatment with rituximab
 influences long-term outcomes.
Inclusion Criteria:

 1. Enrollment in the RAVE trial

 2. Completion of RAVE Common Closeout Date visit

 3. Informed consent

 Exclusion Criteria:

 1. Refusal to participate

 2. Inability to comply with standard-of-care, including routine clinical visits and
 testing.